MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant bacterial infections, recently announced ...
Singapore, 6 June 2023 - Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research ...
GARDEN CITY, N.Y., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for ...
Epetraborole’s potent activity against M. abscessus supports further investigation as a potential therapy for disease with an estimated all-cause mortality of 45% AN2 Therapeutics, Inc. (Nasdaq: ANTX) ...
Background. Mycobacterium abscessus and Mycobacterium massiliense, which cause lung disease, are variable in their clinical manifestation and progression. We hypothesized that mycobacterial genotypes ...
At the center of this resistance is the WhiB7 “resistome,” a set of antibiotic-limiting genes in M. abscessus. “WhiB7 is a master regulator of ribosomal stress, and many antibiotics used to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results